Table 1.
Mean health utility by disease state
|
Disease state |
N* |
Health utility |
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| UK | 95% LCL | 95% UCL | NL | 95% LCL | 95% UCL | ||
| Asymptomatic |
** |
0.93 |
0.8900 |
0.9700 |
0.93 |
0.8900 |
0.9700 |
| Symptoms/recovery |
17 |
0.8716 |
0.8177 |
0.9225 |
0.8897 |
0.8410 |
0.9349 |
| Splenectomy |
4 |
0.7532 |
0.6768 |
0.8215 |
0.7781 |
0.6990 |
0.8626 |
| Bone complication |
6 |
0.8614 |
0.7530 |
0.9685 |
0.8882 |
0.8027 |
0.9707 |
| Multiple complications |
13 |
0.7323 |
0.6601 |
0.8202 |
0.7981 |
0.7430 |
0.8638 |
| Malignancy | 1# | 0.15 | 0.364 | ||||
LCL: lower limit of the confidence interval, UCL: upper limit of the confidence interval.
*Patients may contribute to more than one disease state.
**We used a foreign estimate of 0.93 (95% CI: 0.89-0.97) for healthy persons reported by Clarke et al. [16]. This estimate too was based on time trade-off based elicitation techniques.
#The observed estimate for the stage of malignancy was based on just 1 person, but well within the range of values expected for end-stage malignant disease (e.g. Brown et al. [17]).